Drug Information

Drug General Information
Drug ID
D01UUD
Former ID
DNCL003130
Drug Name
Pitolisant
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Phase 3 [524221]
Company
Bioprojet; Ferrer
Formula
C17H26ClNO
Canonical SMILES
C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
InChI
1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2
InChIKey
NNACHAUCXXVJSP-UHFFFAOYSA-N
PubChem Compound ID
9948102
PubChem Substance ID
14922700, 24219069, 57373865, 76236908, 103590504, 104102226, 134346295, 135267132, 136061457, 137014530, 139406634, 152258405, 160647242, 162223312, 162510281, 185985203, 198942557, 202535639, 224056376, 226489682, 252480498
Target and Pathway
Target(s) Histamine H3 receptor Target Info Agonist [532787]
KEGG Pathway Neuroactive ligand-receptor interaction
Reactome Histamine receptors
G alpha (i) signalling events
WikiPathways Monoamine Transport
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 524221ClinicalTrials.gov (NCT01800045) Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP). U.S. National Institutes of Health.
Ref 532787Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. Sleep Med. 2014 Jun;15(6):681-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.